Anticancer Therapies – Products

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

This literature review explores the latest in 3D immune cell killing assays for cancer immunotherapy research.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.

Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

Thermo Fisher announced a first of its kind technology to help accelerate the molecule-to-market process by driving efficiency and reducing manufacturing costs.

With six CAR-T drugs currently approved by the FDA and more to follow, Sino Biological has committed to developing reagents and services to support our clients in CAR development, CAR-T preparation and lentivirus packaging, CAR-T cell expansion, and CAR-T quality control.

Sino Biological performs extensive quality control tests to ensure that GMP-grade cytokines meet rigorous quality standards, offering a range of GMP-grade cytokines

During this webinar, we will provide a comprehensive overview of several cytokine therapy approaches, development, and clinical application. We will further discuss how Sino Biological can assist in cancer immunotherapy research.